Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Evotec Se (EVO)

Evotec Se (EVO)
3.29 x 1 3.53 x 1
Post-market by (Cboe BZX)
3.41 -0.10 (-2.85%) 03/26/25 [NASDAQ]
3.29 x 1 3.53 x 1
Post-market 3.41 unch (unch) 16:00 ET
Quote Overview for Wed, Mar 26th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
3.41
Day High
3.49
Open 3.49
Previous Close 3.51 3.51
Volume 21,100 21,100
Avg Vol 120,500 120,500
Stochastic %K 32.31% 32.31%
Weighted Alpha -46.49 -46.49
5-Day Change -0.20 (-5.54%) -0.20 (-5.54%)
52-Week Range 2.85 - 7.98 2.85 - 7.98
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,243,842
  • Shares Outstanding, K 354,371
  • Annual Sales, $ 845,740 K
  • Annual Income, $ -90,820 K
  • EBIT $ -175 M
  • EBITDA $ -74 M
  • 60-Month Beta 1.47
  • Price/Sales 1.44
  • Price/Cash Flow 131.10
  • Price/Book 1.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.03
  • Number of Estimates 2
  • High Estimate 0.09
  • Low Estimate -0.04
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.35 +1.79%
on 03/13/25
Period Open: 4.30
4.47 -23.71%
on 02/27/25
-0.89 (-20.70%)
since 02/26/25
3-Month
3.35 +1.79%
on 03/13/25
Period Open: 4.88
4.76 -28.36%
on 02/06/25
-1.47 (-30.12%)
since 12/26/24
52-Week
2.85 +19.65%
on 08/08/24
Period Open: 7.45
7.98 -57.27%
on 04/08/24
-4.04 (-54.23%)
since 03/26/24

Most Recent Stories

More News
Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb

Ongoing strategic partnership advances joint pipeline in neurodegeneration research

EVO : 3.41 (-2.85%)
BMY : 59.21 (+0.03%)
Evotec Announces Change in Management Board

Laetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025

EVO : 3.41 (-2.85%)
Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases

Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and Energy

EVO : 3.41 (-2.85%)
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk

Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing...

EVT : 23.54 (-0.17%)
EVO : 3.41 (-2.85%)
Evotec Announces Change in Management Board

Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024

EVO : 3.41 (-2.85%)
HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up

Halozyme Therapeutics, Inc. HALO announced that it has withdrawn its non-binding proposal to acquire Evotec SE EVO for €11.00 per share in cash. The acquisition offer implied a fully diluted equity value...

CSTL : 20.08 (-3.65%)
SPRO : 0.8900 (-1.00%)
HALO : 63.82 (-1.57%)
EVO : 3.41 (-2.85%)
Comment on Withdrawn Non-Binding Offer

HAMBURG, GERMANY / ACCESSWIRE / November 22, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480)(NASDAQ:EVO)

EVT : 23.54 (-0.17%)
EVO : 3.41 (-2.85%)
Just - Evotec Biologics Opens Cutting-Edge Biologics Facility - J.POD(R) Toulouse, France (EU)

J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region

EVT : 23.54 (-0.17%)
EVO : 3.41 (-2.85%)
Evotec SE Provides Guidance Update

HAMBURG, GERMANY / ACCESSWIRE / August 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it has refined its...

EVO : 3.41 (-2.85%)
RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced today that Leesa Gentry has joined the Company...

RNXT : 1.0200 (-3.77%)
EVO : 3.41 (-2.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of...

See More

Key Turning Points

3rd Resistance Point 3.54
2nd Resistance Point 3.52
1st Resistance Point 3.46
Last Price 3.41
1st Support Level 3.38
2nd Support Level 3.36
3rd Support Level 3.30

See More

52-Week High 7.98
Fibonacci 61.8% 6.02
Fibonacci 50% 5.41
Fibonacci 38.2% 4.81
Last Price 3.41
52-Week Low 2.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies